Correlation Between Inozyme Pharma and Curative Biotechnology
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Curative Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Curative Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Curative Biotechnology, you can compare the effects of market volatilities on Inozyme Pharma and Curative Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Curative Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Curative Biotechnology.
Diversification Opportunities for Inozyme Pharma and Curative Biotechnology
-0.3 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Inozyme and Curative is -0.3. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Curative Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Curative Biotechnology and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Curative Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Curative Biotechnology has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Curative Biotechnology go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Curative Biotechnology
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Curative Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 16.92 times less risky than Curative Biotechnology. The stock trades about -0.01 of its potential returns per unit of risk. The Curative Biotechnology is currently generating about 0.08 of returns per unit of risk over similar time horizon. If you would invest 2.50 in Curative Biotechnology on November 9, 2024 and sell it today you would lose (1.25) from holding Curative Biotechnology or give up 50.0% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 95.74% |
| Values | Daily Returns |
Inozyme Pharma vs. Curative Biotechnology
Performance |
| Timeline |
| Inozyme Pharma |
| Curative Biotechnology |
Inozyme Pharma and Curative Biotechnology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Curative Biotechnology
The main advantage of trading using opposite Inozyme Pharma and Curative Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Curative Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Curative Biotechnology will offset losses from the drop in Curative Biotechnology's long position.| Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
| Curative Biotechnology vs. Biotron Limited | Curative Biotechnology vs. biOasis Technologies | Curative Biotechnology vs. Covalon Technologies | Curative Biotechnology vs. Mosaic Immunoengineering |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |